Navigation Links
Chem Rx to Present at Bear Stearns 20th Annual Healthcare Conference
Date:9/4/2007

NEW YORK, Sept. 4 /PRNewswire-FirstCall/ -- Paramount Acquisition Corp. (OTC Bulletin Board: PMQC, PMQCU, PMQCW), a special purpose acquisition corporation, announced today that Chem Rx, a major privately-owned long-term care pharmacy based in Long Beach, New York, will present at the Bear Stearns 20th Annual Healthcare Conference, which is being held on September 10 and 11 in New York, NY.

Steven Silva, Executive Vice President and Chief Operating Officer, Jerry Silva, President, Chief Executive Officer and Chairman, and Chuck Kelly, Chief Financial Officer, will present at the conference.

Date: Monday, September 10, 2007

Place: Grand Hyatt Hotel, New York, NY

Time: 4:00 PM ET

A live Webcast of Chem Rx's presentation at 4:00 PM ET will be available on the investor relations section of Chem Rx's website at: http://www.chemrx.net. A replay of the presentation will be available through Monday, September 24, 2007.

ABOUT CHEM RX

Founded more than 40 years ago, Chem Rx is a major, privately-owned long- term care pharmacy serving the New York City metropolitan area, as well as parts of New Jersey and Pennsylvania. Chem Rx's client base includes skilled nursing facilities and a wide range of other long-term care facilities. Chem Rx provides to more than 60,000 residents prescription and non-prescription drugs, intravenous medications, durable medical equipment items and surgical supplies. Chem Rx's website address is http://www.chemrx.net.

ABOUT PARAMOUNT ACQUISITION CORP.

Paramount Acquisition Corp. is a special purpose acquisition corporation that was formed for the specific purpose of effecting a merger, capital stock exchange, asset acquisition, or other similar business combination with an operating business in the healthcare industry. Paramount raised net proceeds of approximately $5
'/>"/>

SOURCE Paramount Acquisition Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... 18, 2014) Benaroya Research Institute at Virginia Mason ... a particular molecule in metastatic breast cancer reduces both ... lung metastases. BRI scientists have found in models of ... by 60 - 80 percent and can keep the ... $1.8 million five-year grant comes from the National Cancer ...
(Date:4/18/2014)... ― A new study in the American Journal ... Google searches reveals a recurring pattern that could be ... Investigators from San Diego State University, the Santa Fe ... "healthy" Google searches (searches that included the term healthy ... the U.S. from 2005 to 2012. They found that ...
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2
... exposure can produce more than some tanners may bargain ... to treat skin eruptions, according to research conducted by ... "There are many reasons to be cautious ... beds to ,self-treat, skin eruptions," said Jeffrey B. Travers, ...
... small subset of normal white blood cells in the body ... The study, led by investigators at The Ohio State ... and Richard J. Solove Research Institute (OSUCCC James), shows ... subset of white blood cells called NKT cells. NKT cells ...
... , CHAMPAIGN, lll. A review of more than 160 ... compelling evidence" that all else being equal happy ... their unhappy peers. The study, in the journal ... review so far of the evidence linking happiness to health ...
... (HealthDay News) -- The use of virtual colonoscopies at U.S. ... not covered by Medicare, a new study finds. Also ... uses virtual reality technology to provide doctors with a 3-D ... entire colon and rectum. CTC is an alternative to colonoscopy ...
... WIREs Nanomedicine and Nanobiotechnology explores how nanotechnology ... marked impact on the therapeutic and diagnostic measures available ... a meterto achieve tasks that would be difficult at ... and can enter cells, making them useful for drug ...
... been on the rise in the United States. In fact, ... vehicle crash fatalities to become the leading cause of injury ... reported, they are only the tip of the iceberg. ... Research and Policy of The Research Institute at Nationwide Children,s ...
Cached Medicine News:Health News:Tanning bed exposure can be deadly when complicated by medication reactions 2Health News:A small subset of normal white blood cells gives rise to a rare leukemia, study shows 2Health News:Study: Happiness improves health and lengthens life 2Health News:Surgeons predict the future of nanomedicine in practice 2Health News:New study: Medical and financial impact of drug-related poisonings treated in US EDs 2
(Date:1/15/2014)... /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from ... China,s orthopedic instrument industry has seen ... rising from 3.28 billion yuan in 2006 to 9.85 ...
(Date:1/15/2014)... 2014 AARP Foundation today announced it has established a ... the severe cold weather that has gripped much of the ... in need; so to support these emergency relief efforts AARP ... which could mean up to $500,000 in aid. The matching ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Through Joint Venture Between Bristol-Myers Squibb and ... Its Kind in HIV Treatment -, PRINCETON, N.J. ... Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz 600 mg/emtricitabine ... commercialization in the,27 countries of the European Union, as ...
... novel combination of drugs was,able to completely eradicate ... for the effective treatment of patients with advanced,metastatic ... University,School of Medicine presented the results of a ... pulmonary metastases in female SCID,mice., Paclitaxel is ...
Cached Medicine Technology:European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9New Drug Combination is Able to Eradicate Breast Metastases in Mice 2